First step: testing new obesity Drug's safety in people with kidney issues
NCT ID NCT07141030
Summary
This early-stage study aims to understand how a new injectable drug called GZR18 is processed by the body in people with normal and impaired kidney function. It will enroll 32 adults with overweight or obesity to measure drug levels and safety after a single dose. The goal is to gather data to help determine safe and effective dosing for future patients who have kidney problems.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY & OVERWEIGHT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Gan & Lee Pharmaceuticals
RECRUITINGBeijing, China
Conditions
Explore the condition pages connected to this study.